The structure of dopamine induced α-synuclein oligomers

被引:0
作者
Agata Rekas
Robert B. Knott
Anna Sokolova
Kevin J. Barnham
Keyla A. Perez
Colin L. Masters
Simon C. Drew
Roberto Cappai
Cyril C. Curtain
Chi L. L. Pham
机构
[1] Australian Nuclear Science and Technology Organisation (ANSTO),Department of Pathology
[2] The University of Melbourne,Bio21 Molecular Science and Technology Institute
[3] The University of Melbourne,School of Physics
[4] Mental Health Research Institute,undefined
[5] Monash University,undefined
[6] ANSTO,undefined
来源
European Biophysics Journal | 2010年 / 39卷
关键词
Parkinson’s disease; α-Synuclein; Dopamine; Protein aggregation; SAXS; CD spectroscopy; EPR spectroscopy; Sedimentation velocity analysis;
D O I
暂无
中图分类号
学科分类号
摘要
Inclusions of aggregated α-synuclein (α-syn) in dopaminergic neurons are a characteristic histological marker of Parkinson’s disease (PD). In vitro, α-syn in the presence of dopamine (DA) at physiological pH forms SDS-resistant non-amyloidogenic oligomers. We used a combination of biophysical techniques, including sedimentation velocity analysis, small angle X-ray scattering (SAXS) and circular dichroism spectroscopy to study the characteristics of α-syn oligomers formed in the presence of DA. Our SAXS data show that the trimers formed by the action of DA on α-syn consist of overlapping worm-like monomers, with no end-to-end associations. This lack of structure contrasts with the well-established, extensive β-sheet structure of the amyloid fibril form of the protein and its pre-fibrillar oligomers. We propose on the basis of these and earlier data that oxidation of the four methionine residues at the C- and N-terminal ends of α-syn molecules prevents their end-to-end association and stabilises oligomers formed by cross linking with DA-quinone/DA-melanin, which are formed as a result of the redox process, thus inhibiting formation of the β-sheet structure found in other pre-fibrillar forms of α-syn.
引用
收藏
页码:1407 / 1419
页数:12
相关论文
共 254 条
[1]  
Barnham KJ(2006)Delineating common molecular mechanisms in Alzheimer’s and prion diseases Trends Biochem Sci 31 465-472
[2]  
Cappai R(2005)Release of long-range tertiary interactions potentiates aggregation of natively unstructured alpha-synuclein Proc Natl Acad Sci USA 102 1430-1435
[3]  
Beyreuther K(2008)Aggregation of alpha-synuclein by DOPAL, the monoamine oxidase metabolite of dopamine Acta Neuropathol 115 193-203
[4]  
Masters CL(2005)Dopamine promotes alpha-synuclein aggregation into SDS-resistant soluble oligomers via a distinct folding pathway Faseb J 19 1377-1379
[5]  
Hill AF(2008)In vivo alpha-synuclein overexpression in rodents: a useful model of Parkinson’s disease? Exp Neurol 209 22-27
[6]  
Bertoncini CW(2000)Acceleration of oligomerisation, not fibrillization, is a shared property of both α-synuclein mutations linked to early-onset Parkinson’s disease: implications for pathogenesis and therapy Proc Natl Acad Sci USA 97 571-576
[7]  
Jung YS(2001)Kinetic stabilization of the α-synuclein protofibril by a dopamine-α-synuclein adduct Science 294 1346-1349
[8]  
Fernandez CO(2005)Structure and properties of alpha-synuclein and other amyloids determined at the amino acid level Proc Natl Acad Sci USA 102 15477-15482
[9]  
Hoyer W(1998)Effects of the mutations Ala FEBS Lett 440 67-70
[10]  
Griesinger C(2004) to Pro and Ala Proc Natl Acad Sci USA 101 12497-12502